Defining the Role of of Noncanonical GPCR Signalling in Pulmonary Hypertension
定义非典型 GPCR 信号在肺动脉高压中的作用
基本信息
- 批准号:10544136
- 负责人:
- 金额:$ 3.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:Angiotensin II ReceptorArrestinsBiochemicalBiological AssayBiotinCardiovascular systemCell LineCell physiologyComplexCouplingDevelopmentDiseaseDrug TargetingDrug usageEndosomesEndothelial CellsEndotheliumEngineeringEventExtracellular Signal Regulated KinasesFDA approvedG Protein-Coupled Receptor SignalingG-Protein-Coupled ReceptorsGTP-Binding ProteinsGenomeGoalsHarvestHealthHeterotrimeric GTP-Binding ProteinsImpairmentKnowledgeLabelLigandsMedicalMissionMutatePathway interactionsPatientsPeroxidasesPharmaceutical PreparationsPharmacologyPhysiologicalPhysiologyPlayProteinsPulmonary HypertensionReceptor, Angiotensin, Type 1ResearchRoleScientistSignal PathwaySignal TransductionSystemTestingTherapeuticTrainingTubeUnited States National Institutes of HealthVariantVascular remodelingWorkascorbatebasechemokine receptordesensitizationendothelial dysfunctioninsightmigrationnanoluciferasenovelnovel therapeuticspreferencepublic health relevancepulmonary artery endothelial cellpulmonary vascular disorderreceptorreceptor functionreceptor internalizationright ventricular failuretooltraffickingvasoconstriction
项目摘要
ABSTRACT
Pulmonary hypertension (PH) is characterized by endothelial dysfunction, irregular vascular remodeling and
consistent vasoconstriction leading to eventual fatal right heart failure despite current medical therapies. The
most common drug targets in PH are G protein coupled receptors (GPCRs), which are a target for almost a
third of all FDA-approved drugs. Although these receptors have been studied intensely for over 40 years,
several aspects of GPCR signaling remain poorly understood. Canonically, it has been well established that
these receptors are able to signal through both heterotrimeric G proteins and β-arrestins (βarrs). These events
were thought to be largely separable given that G proteins primarily initiate downstream signaling while βarrs
can signal and regulate receptor desensitization and trafficking. Recent studies have suggested evidence
for a combined role of G protein and βarr in GPCRs signaling through the formation of signaling
“megaplexes” and the impairment of βarr-based signaling in the absence of functional G proteins. However,
there remains a significant knowledge gap surrounding the significance of G protein and βarr coordinated
signaling. Our long term aim is to understand the signaling mechanisms of GPCRs to provide better insight for
the development of novel therapeutics for PH. In our recent studies, we have directly assessed whether G
proteins and βarrs can interact across a panel receptors and were surprised to find that all receptors tested
could form a complex between the inhibitory G protein (Gαi) and βarr, including the type 1 angiotensin II
receptor (AT1R) and atypical chemokine receptor 3 (ACKR3, also known as CXCR7), which are both potential
drug targets in PH. We further found that these complexes could interact with secondary effectors, most
notably extracellular signal-regulated kinase (ERK). These results suggested a conserved, non-canonical
role for Gαi:βarr signaling across GPCRs. Our overarching goal is to define the mechanism in which
Gαi:βarr form complexes and understand their impact on physiology. We hypothesize that Gαi:βarr complex
formation require a discrete set of motifs present in Gαi, βarrs and GPCRs and that these complexes regulate
endothelial function in PH. To test this hypothesis, first I will determine the specific sequence motifs in Gαi, βarr
and the receptor that are required to form Gαi:βarr complex. Second, I will determine the signalling pathways
that are regulated by Gαi:βarr interaction using APEX proximity labeling and novel “complex BRET” assays.
Third, I will determine the impact of Gai:βarr within PH patient endothelial cells by targeting Gαi and βarr
signaling and testing their effects on endothelial function. This study strives to understand an emerging
paradigm in GPCR signalling in which Gαi and βarr work together to orchestrate unique downstream signalling.
Completion of these aims will provide novel insights for cell signalling, development of new pharmacological
tools targeting Gαi:βarr coupling, and lay the groundwork for therapeutics for cardiovascular-related diseases.
These studies will also provide an excellent opportunity for my training to develop as an independent scientist.
摘要
肺动脉高压(PH)的特征是内皮功能障碍、不规则血管重构和血管内皮细胞损伤。
持续的血管收缩导致最终致命的右心衰竭,尽管目前的药物治疗。的
PH中最常见的药物靶点是G蛋白偶联受体(GPCR),它是几乎所有PH的靶点。
三分之一的FDA批准的药物。尽管这些受体已经被深入研究了40多年,
GPCR信号传导的几个方面仍然知之甚少。从规范上讲,
这些受体能够通过异源三聚体G蛋白和β-抑制蛋白(βarrs)两者发出信号。这些事件
考虑到G蛋白主要启动下游信号传导,而βarrs主要启动下游信号传导,
可以发出信号并调节受体脱敏和运输。最近的研究表明
对于G蛋白和β-内酰胺酶在GPCR信号传导中通过形成信号传导的组合作用,
“megaplexes”和功能性G蛋白缺失时基于β arr的信号传导受损。然而,在这方面,
围绕G蛋白和β-内酰胺酶协调的重要性,
发信号。我们的长期目标是了解GPCR的信号传导机制,以便更好地了解
在我们最近的研究中,我们直接评估了G
蛋白质和βarrs可以通过a组受体相互作用,
抑制性G蛋白(Gαi)与β-D-半乳糖苷酶(β-D-半乳糖苷酶),包括1型血管紧张素II(Ang II),
受体(AT 1 R)和非典型趋化因子受体3(ACKR 3,也称为CXCR 7),它们都是潜在的
我们进一步发现这些复合物可以与次级效应物相互作用,
特别是细胞外信号调节激酶(ERK)。这些结果表明,一个保守的,非典型的
Gαi的作用:GPCR中的β 1信号传导。我们的首要目标是定义一种机制,
Gαi:β I形成复合物并了解其对生理学的影响。我们假设Gαi:β I复合物
形成需要存在于Gαi、βarrs和GPCR中的一组离散的基序,并且这些复合物调节
为了验证这一假设,首先我将确定Gαi、β i和β i中的特定序列基序,
以及形成Gαi:β I复合物所需的受体。第二,我将确定信号通路
使用APEX邻近标记和新的“复合BRET”测定法,
第三,我将通过靶向Gαi和β i来确定Gai:β i在PH患者内皮细胞内的影响。
信号传导并测试它们对内皮功能的影响。本研究旨在了解一种新兴的
在GPCR信号传导的范例中,Gαi和β i共同作用以协调独特的下游信号传导。
这些目标的完成将为细胞信号传导、新药理学的开发提供新的见解
靶向Gαi:β I偶联的工具,并为心血管相关疾病的治疗奠定基础。
这些研究也将为我的培训提供一个极好的机会,使我成为一名独立的科学家。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Claudia Y Lee其他文献
emIn Vivo/em CAR Delivery As Supercoiled DNA with Polyasparagine Nanoparticles
体内/em 嵌合抗原受体(CAR)以超螺旋 DNA 与聚天冬酰胺纳米粒子的形式递送
- DOI:
10.1182/blood-2024-210030 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:23.100
- 作者:
Claudia Y Lee;Grig Zhang;Chris Y Coker;Sisi Zheng - 通讯作者:
Sisi Zheng
<em>In Vivo</em> CAR Delivery As Supercoiled DNA with Polyasparagine Nanoparticles
- DOI:
10.1182/blood-2024-210030 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Claudia Y Lee;Grig Zhang;Chris Y Coker;Sisi Zheng - 通讯作者:
Sisi Zheng
Claudia Y Lee的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Claudia Y Lee', 18)}}的其他基金
Defining the Role of of Noncanonical GPCR Signalling in Pulmonary Hypertension
定义非典型 GPCR 信号在肺动脉高压中的作用
- 批准号:
10669247 - 财政年份:2021
- 资助金额:
$ 3.77万 - 项目类别:
相似国自然基金
AT1R-G蛋白/β-arrestins通路偏好性激活在急性肾损伤中的作用及其机制
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
催产素受体Gαq与β-arrestins偏爱型信号通路在产后抑郁症中的作用
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
β-arrestins在DC细胞迁移及自身免疫疾病中的作用及机制研究
- 批准号:31871404
- 批准年份:2018
- 资助金额:60.0 万元
- 项目类别:面上项目
β-arrestins调节小胶质细胞M1/M2表型转化及其在阿尔兹海默病进程中的作用
- 批准号:81703488
- 批准年份:2017
- 资助金额:20.1 万元
- 项目类别:青年科学基金项目
β-arrestins保护心肌梗死的作用和机制研究
- 批准号:81670260
- 批准年份:2016
- 资助金额:57.0 万元
- 项目类别:面上项目
beta-arrestins在自感光神经节细胞光信号转导中的作用和机制研究
- 批准号:31601134
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
β-arrestins通过ER stress/Puma调控门脉高压性胃病的机制
- 批准号:81370511
- 批准年份:2013
- 资助金额:75.0 万元
- 项目类别:面上项目
支气管上皮细胞恶性转化中β-arrestins的作用及其机制研究
- 批准号:81301728
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
β-arrestins介导甘丙肽2型受体信号转导的作用机理及其可能的抗抑郁机制
- 批准号:31171032
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
β-arrestins在缺血再灌注性肝损伤及其修复中的作用和机制
- 批准号:81170422
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 3.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Collaborative Research: Alpha-arrestins' impact on cellular physiology
合作研究:α-抑制蛋白对细胞生理学的影响
- 批准号:
2321625 - 财政年份:2023
- 资助金额:
$ 3.77万 - 项目类别:
Standard Grant
Collaborative Research: Alpha-arrestins' impact on cellular physiology
合作研究:α-抑制蛋白对细胞生理学的影响
- 批准号:
2321624 - 财政年份:2023
- 资助金额:
$ 3.77万 - 项目类别:
Standard Grant
Structure and function of mGluR3 interactions with beta-arrestins and the membrane.
mGluR3 与 β-arrestins 和膜相互作用的结构和功能。
- 批准号:
10704588 - 财政年份:2022
- 资助金额:
$ 3.77万 - 项目类别:
Structure and function of mGluR3 interactions with beta-arrestins and the membrane.
mGluR3 与 β-arrestins 和膜相互作用的结构和功能。
- 批准号:
10536255 - 财政年份:2022
- 资助金额:
$ 3.77万 - 项目类别:
FASEB SRC: The G Protein-coupled Receptor Kinases and Arrestins Conference: Key Modulators of Signal Transduction
FASEB SRC:G 蛋白偶联受体激酶和抑制蛋白会议:信号转导的关键调节剂
- 批准号:
10464336 - 财政年份:2022
- 资助金额:
$ 3.77万 - 项目类别:
Regulation of the metastasis promoting chemokine receptor ACKR3 by GPCR kinases, Gβγ and arrestins
GPCR 激酶、Gβγ 和抑制蛋白对促进趋化因子受体 ACKR3 的转移的调节
- 批准号:
10627751 - 财政年份:2020
- 资助金额:
$ 3.77万 - 项目类别:
Regulation of the metastasis promoting chemokine receptor ACKR3 by GPCR kinases, Gβγ and arrestins
GPCR 激酶、Gβγ 和抑制蛋白对促进趋化因子受体 ACKR3 的转移的调节
- 批准号:
10397636 - 财政年份:2020
- 资助金额:
$ 3.77万 - 项目类别:
Regulation of the metastasis promoting chemokine receptor ACKR3 by GPCR kinases, Gβγ and arrestins
GPCR 激酶、Gβγ 和抑制蛋白对促进趋化因子受体 ACKR3 的转移的调节
- 批准号:
10162570 - 财政年份:2020
- 资助金额:
$ 3.77万 - 项目类别:














{{item.name}}会员




